Literature DB >> 23764638

Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations.

Connie Celum1, Jared M Baeten, James P Hughes, Ruanne Barnabas, Albert Liu, Heidi Van Rooyen, Susan Buchbinder.   

Abstract

Combination HIV prevention is of high priority for increasing the impact of partially efficacious HIV prevention interventions for specific populations and settings. Developing the package requires critical review of local epidemiology of HIV infection regarding most-impacted populations and those at high risk of HIV transmission and acquisition, drivers of HIV infection, and available interventions to address these risk factors. Interventions should be considered in terms of the evidence basis for efficacy, potential synergies, and feasibility of delivery at scale, which is important to achieve high coverage and impact, coupled with high acceptability to populations, which will impact uptake, adherence, and retention. Evaluation requires process measures of uptake, adherence, retention, and outcome measures of reduction in HIV infectiousness and acquisition. Three examples of combination prevention concepts are summarized for men who have sex with men in the Americas, young women in sub-Saharan Africa, and HIV serodiscordant couples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764638      PMCID: PMC3708491          DOI: 10.1097/QAI.0b013e3182986f3a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  73 in total

1.  Understanding the HIV/AIDS epidemic in transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven sampling.

Authors:  Alfonso Silva-Santisteban; H Fisher Raymond; Ximena Salazar; Jana Villayzan; Segundo Leon; Willi McFarland; Carlos F Caceres
Journal:  AIDS Behav       Date:  2012-05

2.  Maternal deaths averted by contraceptive use: an analysis of 172 countries.

Authors:  Saifuddin Ahmed; Qingfeng Li; Li Liu; Amy O Tsui
Journal:  Lancet       Date:  2012-07-10       Impact factor: 79.321

3.  High levels of acceptability of couples-based HIV testing among MSM in South Africa.

Authors:  Rob Stephenson; Christopher Rentsch; Patrick Sullivan
Journal:  AIDS Care       Date:  2011-10-18

Review 4.  Global epidemiology of HIV infection in men who have sex with men.

Authors:  Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer
Journal:  Lancet       Date:  2012-07-20       Impact factor: 79.321

5.  What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.

Authors:  Norma C Ware; Monique A Wyatt; Jessica E Haberer; Jared M Baeten; Alexander Kintu; Christina Psaros; Steven Safren; Elioda Tumwesigye; Connie L Celum; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

6.  Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.

Authors:  K R Amico; Vanessa McMahan; Pedro Goicochea; Lorena Vargas; Julia L Marcus; Robert M Grant; Albert Liu
Journal:  AIDS Behav       Date:  2012-07

Review 7.  HIV-1 prevention for HIV-1 serodiscordant couples.

Authors:  Kathryn Curran; Jared M Baeten; Thomas J Coates; Ann Kurth; Nelly R Mugo; Connie Celum
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

8.  Economics of antiretroviral treatment vs. circumcision for HIV prevention.

Authors:  Till Bärnighausen; David E Bloom; Salal Humair
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-06       Impact factor: 11.205

9.  High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa.

Authors:  Sheree R Schwartz; Helen Rees; Shruti Mehta; Willem Daniel Francois Venter; Taha E Taha; Vivian Black
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

10.  HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Authors:  Gesine Meyer-Rath; Mead Over
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

View more
  13 in total

1.  Will risk compensation accompany pre-exposure prophylaxis for HIV?

Authors:  Jill Blumenthal; Richard H Haubrich
Journal:  Virtual Mentor       Date:  2014-11-01

Review 2.  Advances in HIV prevention for serodiscordant couples.

Authors:  Kathryn E Muessig; Myron S Cohen
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

3.  Safety and tolerability of tenofovir for preexposure prophylaxis among men who have sex with men.

Authors:  Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

4.  The lifetime medical cost savings from preventing HIV in the United States.

Authors:  Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina
Journal:  Med Care       Date:  2015-04       Impact factor: 2.983

5.  High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.

Authors:  Stephanie E Cohen; Eric Vittinghoff; Oliver Bacon; Susanne Doblecki-Lewis; Brian S Postle; Daniel J Feaster; Tim Matheson; Nikole Trainor; Robert W Blue; Yannine Estrada; Megan E Coleman; Richard Elion; Jose G Castro; Wairimu Chege; Susan S Philip; Susan Buchbinder; Michael A Kolber; Albert Y Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

Review 6.  HIV Prevention Interventions for Adolescents.

Authors:  Sybil Hosek; Audrey Pettifor
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

7.  Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Authors:  Jared M Baeten; Deborah Donnell; Nelly R Mugo; Patrick Ndase; Katherine K Thomas; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Robert W Coombs; Craig Hendrix; Mark A Marzinke; Lisa Frenkel; Jessica E Haberer; David Bangsberg; Connie Celum
Journal:  Lancet Infect Dis       Date:  2014-10-07       Impact factor: 25.071

8.  PrEP Implementation Science: State-of-the-Art and Research Agenda.

Authors:  Carlos F Cáceres; Kenneth H Mayer; Rachel Baggaley; Kevin R O'Reilly
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

9.  Tailored combination prevention packages and PrEP for young key populations.

Authors:  Audrey Pettifor; Nadia L Nguyen; Connie Celum; Frances M Cowan; Vivian Go; Lisa Hightow-Weidman
Journal:  J Int AIDS Soc       Date:  2015-02-26       Impact factor: 5.396

10.  Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.

Authors:  Roger Ying; Monisha Sharma; Renee Heffron; Connie L Celum; Jared M Baeten; Elly Katabira; Nulu Bulya; Ruanne V Barnabas
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.